Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zongertinib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer Harboring HER2 Mutations
NCT07619066Phase 2Not yet recruiting
- Sponsor
- MEDSIR
- Start
- Oct 2026
- Primary completion
- Sep 2028
01
Overview
Phase 2, open-label, single-arm trial of zongertinib in breast cancer, sponsored by MEDSIR. Primary endpoint: Objective Response Rate at 6 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
zongertinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07619066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619066.